This database contains 664 studies, archived under the term: "Randomised Controlled Trial"
Click here to filter this large number of results.
Donepezil delays progression to AD in MCI subjects with depressive symptoms
Lu, P. H.,
Edland, S. D.,
Teng, E.,
Tingus, K.,
Petersen, R. C.,
Cummings, J. L.
Objective: To determine whether the presence of depression predicts higher rate of progression to Alzheimer disease (AD) in patients with amnestic mild cognitive impairment (aMCI) and whether donepezil treatment beneficially affect this relationship.; Methods: The study sample was composed of 756 participants with aMCI from the 3-year, double-blind, placebo-controlled Alzheimer’s Disease Cooperative Study drug trial […]
Vitamin E paradox in Alzheimer’s disease: it does not prevent loss of cognition and may even be detrimental
Lloret, Ana,
Badía, Mari-Carmen,
Mora, Nancy J.,
Pallardó, Federico V.,
Alonso, Maria-Dolores,
Viña, Jose
There is controversy as to whether vitamin E is beneficial in Alzheimer’s disease (AD). In this study, we tested if vitamin E prevents oxidative stress and loss of cognition in AD. Fifty-seven AD patients were recruited and divided in two groups: placebo or treated with 800 IU of vitamin E per day for six months. […]
Using acupressure and Montessori-based activities to decrease agitation for residents with dementia: a cross-over trial
Lin, Li-Chan,
Yang, Man-Hua,
Kao, Chieh-Chun,
Wu, Shiao-Chi,
Tang, Sai-Hung,
Lin, Jaung-Geng
Objectives: To explore the effectiveness of acupressure and Montessori-based activities in decreasing the agitated behaviors of residents with dementia.; Design: A double-blinded, randomized (two treatments and one control; three time periods) cross-over design was used.; Setting: Six special care units for residents with dementia in long-term care facilities in Taiwan were the sites for the […]
Increase of BDNF serum concentration in lithium treated patients with early Alzheimer’s disease
Leyhe, Thomas,
Eschweiler, Gerhard W.,
Stransky, Elke,
Gasser, Thomas,
Annas, Peter,
Basun, Hans,
Laske, Christoph
Preclinical and clinical studies gave evidence that lithium could be useful in the treatment of Alzheimer’s disease (AD). In experimental investigations, lithium induces brain-derived neurotrophic factor (BDNF). Recent studies have found a decrease of BDNF in the serum and brains of AD patients with potentially consecutive lack of neurotrophic support. We assessed the influence of […]
Randomized controlled trial of memantine in dementia associated with Parkinson’s disease
The objective of this study is to investigate the safety and tolerability of memantine, a glutamatergic modulator, in patients suffering from dementia associated with Parkinson’s disease (PDD), an increasingly common complication of PD. This was a 22-week trial of 25 participants with a DSM-IV diagnosis of PDD who were randomized to either placebo or 20 […]
Early intervention for mild cognitive impairment: a randomised controlled trial
Kinsella, G. J.,
Mullaly, E.,
Rand, E.,
Ong, B.,
Burton, C.,
Price, S.,
Phillips, M.,
Storey, E.
Background: Positive effects are reported for memory training for healthy older adults, and yet there is limited information about the benefit of cognitive intervention for older adults with increasing memory difficulties-mild cognitive impairment.; Objective: To investigate the usefulness of an early cognitive intervention for the memory difficulties experienced by people with amnestic mild cognitive impairment.; […]
Effect of music therapy on anxiety and depression in patients with Alzheimer’s type dementia: randomised, controlled study
Guétin, Stéphane,
Portet, F.,
Picot, M. C.,
Pommié, C.,
Messaoudi, M.,
Djabelkir, L.,
Olsen, A. L.,
Cano, M. M.,
Lecourt, E.,
Touchon, J.
Background/aims: Numerous studies have indicated the value of music therapy in the management of patients with Alzheimer’s disease. A recent pilot study demonstrated the feasibility and usefulness of a new music therapy technique. The aim of this controlled, randomised study was to assess the effects of this new music therapy technique on anxiety and depression […]
Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension
Grossberg, George,
Sadowsky, Carl,
Fröstl, Hans,
Frölich, Lutz,
Nagel, Jennifer,
Tekin, Sibel,
Zechner, Stefanie,
Ros, Jacqueline,
Orgogozo, Jean-Marc
The primary objective of the open-label extension was to evaluate the long-term safety and tolerability of a transdermal rivastigmine patch up to 1 year, as a novel approach to treatment in Alzheimer disease. This was a 28-week extension to a 24-week, double-blind, double-dummy, placebo-controlled, and active-controlled study evaluating rivastigmine patches [9.5 mg/24 h (10 cm2) […]